Cargando…

In vivo Characterization of a Selective, Orally Available, and Brain Penetrant Small Molecule GPR139 Agonist

Recently, our group along with another demonstrated that GPR139 can be activated by L-phenylalanine (L-Phe) and L-tryptophan (L-Trp) at physiologically relevant concentrations. GPR139 is discretely expressed in brain, with highest expression in medial habenula. Not only are the endogenous ligands ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoblock, James R., Welty, Natalie, Fraser, Ian, Wyatt, Ryan, Lord, Brian, Lovenberg, Timothy, Liu, Changlu, Bonaventure, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437111/
https://www.ncbi.nlm.nih.gov/pubmed/30949055
http://dx.doi.org/10.3389/fphar.2019.00273
_version_ 1783406895092989952
author Shoblock, James R.
Welty, Natalie
Fraser, Ian
Wyatt, Ryan
Lord, Brian
Lovenberg, Timothy
Liu, Changlu
Bonaventure, Pascal
author_facet Shoblock, James R.
Welty, Natalie
Fraser, Ian
Wyatt, Ryan
Lord, Brian
Lovenberg, Timothy
Liu, Changlu
Bonaventure, Pascal
author_sort Shoblock, James R.
collection PubMed
description Recently, our group along with another demonstrated that GPR139 can be activated by L-phenylalanine (L-Phe) and L-tryptophan (L-Trp) at physiologically relevant concentrations. GPR139 is discretely expressed in brain, with highest expression in medial habenula. Not only are the endogenous ligands catecholamine/serotonin precursors, but GPR139 expressing areas can directly/indirectly regulate the activity of catecholamine/serotonin neurons. Thus, GPR139 appears expressed in an interconnected circuit involved in mood, motivation, and anxiety. The aim of this study was to characterize a selective and brain penetrant GPR139 agonist (JNJ-63533054) in relevant in vivo models. JNJ-63533054 was tested for its effect on c-fos activation in the habenula and dorsal striatum. In vivo microdialysis experiments were performed in freely moving rats to measure basal levels of serotonin or dopamine (DA) in prefrontal cortex (mPFC) and nucleus accumbens (NAc). Finally, the compound was profiled in behavioral models of anxiety, despair, and anhedonia. The agonist (10–30 mg/kg, p.o.) did not alter c-fos expression in medial habenula or dorsal striatum nor neurotransmitter levels in mPFC or NAc. JNJ-63533054 (10 mg/kg p.o.) produced an anhedonic-like effect on urine sniffing, but had no significant effect in tail suspension, with no interaction with imipramine, no effect on naloxone place aversion, and no effect on learned helplessness. In the marble burying test, the agonist (10 mg/kg p.o.) produced a small anxiolytic-like effect, with no interaction with fluoxetine, and no effect in elevated plus maze (EPM). Despite GPR139 high expression in medial habenula, an area with connections to limbic and catecholaminergic/serotoninergic areas, the GPR139 agonist had no effect on c-fos in medial habenula. It did not alter catecholamine/serotonin levels and had a mostly silent signal in in vivo models commonly associated with these pathways. The physiological function of GPR139 remains elusive.
format Online
Article
Text
id pubmed-6437111
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64371112019-04-04 In vivo Characterization of a Selective, Orally Available, and Brain Penetrant Small Molecule GPR139 Agonist Shoblock, James R. Welty, Natalie Fraser, Ian Wyatt, Ryan Lord, Brian Lovenberg, Timothy Liu, Changlu Bonaventure, Pascal Front Pharmacol Pharmacology Recently, our group along with another demonstrated that GPR139 can be activated by L-phenylalanine (L-Phe) and L-tryptophan (L-Trp) at physiologically relevant concentrations. GPR139 is discretely expressed in brain, with highest expression in medial habenula. Not only are the endogenous ligands catecholamine/serotonin precursors, but GPR139 expressing areas can directly/indirectly regulate the activity of catecholamine/serotonin neurons. Thus, GPR139 appears expressed in an interconnected circuit involved in mood, motivation, and anxiety. The aim of this study was to characterize a selective and brain penetrant GPR139 agonist (JNJ-63533054) in relevant in vivo models. JNJ-63533054 was tested for its effect on c-fos activation in the habenula and dorsal striatum. In vivo microdialysis experiments were performed in freely moving rats to measure basal levels of serotonin or dopamine (DA) in prefrontal cortex (mPFC) and nucleus accumbens (NAc). Finally, the compound was profiled in behavioral models of anxiety, despair, and anhedonia. The agonist (10–30 mg/kg, p.o.) did not alter c-fos expression in medial habenula or dorsal striatum nor neurotransmitter levels in mPFC or NAc. JNJ-63533054 (10 mg/kg p.o.) produced an anhedonic-like effect on urine sniffing, but had no significant effect in tail suspension, with no interaction with imipramine, no effect on naloxone place aversion, and no effect on learned helplessness. In the marble burying test, the agonist (10 mg/kg p.o.) produced a small anxiolytic-like effect, with no interaction with fluoxetine, and no effect in elevated plus maze (EPM). Despite GPR139 high expression in medial habenula, an area with connections to limbic and catecholaminergic/serotoninergic areas, the GPR139 agonist had no effect on c-fos in medial habenula. It did not alter catecholamine/serotonin levels and had a mostly silent signal in in vivo models commonly associated with these pathways. The physiological function of GPR139 remains elusive. Frontiers Media S.A. 2019-03-21 /pmc/articles/PMC6437111/ /pubmed/30949055 http://dx.doi.org/10.3389/fphar.2019.00273 Text en Copyright © 2019 Shoblock, Welty, Fraser, Wyatt, Lord, Lovenberg, Liu and Bonaventure. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Shoblock, James R.
Welty, Natalie
Fraser, Ian
Wyatt, Ryan
Lord, Brian
Lovenberg, Timothy
Liu, Changlu
Bonaventure, Pascal
In vivo Characterization of a Selective, Orally Available, and Brain Penetrant Small Molecule GPR139 Agonist
title In vivo Characterization of a Selective, Orally Available, and Brain Penetrant Small Molecule GPR139 Agonist
title_full In vivo Characterization of a Selective, Orally Available, and Brain Penetrant Small Molecule GPR139 Agonist
title_fullStr In vivo Characterization of a Selective, Orally Available, and Brain Penetrant Small Molecule GPR139 Agonist
title_full_unstemmed In vivo Characterization of a Selective, Orally Available, and Brain Penetrant Small Molecule GPR139 Agonist
title_short In vivo Characterization of a Selective, Orally Available, and Brain Penetrant Small Molecule GPR139 Agonist
title_sort in vivo characterization of a selective, orally available, and brain penetrant small molecule gpr139 agonist
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437111/
https://www.ncbi.nlm.nih.gov/pubmed/30949055
http://dx.doi.org/10.3389/fphar.2019.00273
work_keys_str_mv AT shoblockjamesr invivocharacterizationofaselectiveorallyavailableandbrainpenetrantsmallmoleculegpr139agonist
AT weltynatalie invivocharacterizationofaselectiveorallyavailableandbrainpenetrantsmallmoleculegpr139agonist
AT fraserian invivocharacterizationofaselectiveorallyavailableandbrainpenetrantsmallmoleculegpr139agonist
AT wyattryan invivocharacterizationofaselectiveorallyavailableandbrainpenetrantsmallmoleculegpr139agonist
AT lordbrian invivocharacterizationofaselectiveorallyavailableandbrainpenetrantsmallmoleculegpr139agonist
AT lovenbergtimothy invivocharacterizationofaselectiveorallyavailableandbrainpenetrantsmallmoleculegpr139agonist
AT liuchanglu invivocharacterizationofaselectiveorallyavailableandbrainpenetrantsmallmoleculegpr139agonist
AT bonaventurepascal invivocharacterizationofaselectiveorallyavailableandbrainpenetrantsmallmoleculegpr139agonist